MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health Authority

TORONTO, Feb. 7, 2024 /PRNewswire/ – MediPharm Labs Corp. (TSX:LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce receipt of GMP certification for their Barrie, Ontario facility from ANVISA, the governing body of Brazil’s pharmaceutical industry. MediPharm Labs now has GMP certification from the United States FDA, European Union, Australia’s TGA and holds a drug establishment license from Health Canada.

Read more at prnewswire.com

Related news for (MEDIF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.